---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-064755"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2025-07-01T23:59:59+00:00"
generated_at: "2026-05-18T10:00:04.243166+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics appoints Robert C. Jahr as President and CEO, replacing interim CEO

## Summary
- Robert C. Jahr appointed President & CEO effective July 1, 2025; replaces interim CEO Lawrence Kenyon, who remains CFO and board member.
- Base salary $600,000; target annual bonus 70% of base; inducement option for 800,000 shares vesting over 4 years.
- Jahr previously Chief Commercial Officer at Sobi NA (2021-2025); held leadership roles at UCB Pharma and Amgen.
- Severance: 12 months base salary + target bonus on qualifying termination; 18 months base + 150% bonus on termination in connection with change in control.

## SEC filing metadata
- accession: 0001104659-25-064755
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2025-07-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465925064755/0001104659-25-064755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465925064755/tm2519577d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-064755
- JSON: https://secwatch.observer/filing/0001104659-25-064755.json
- Plain text: https://secwatch.observer/filing/0001104659-25-064755.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.